General
Preferred name
ABACAVIR
Synonyms
Epzicom ()
Ziagen ()
Abacavir hemisulfate ()
1592U89 ()
ABC sulfate ()
ABACAVIR SULFATE ()
Triumeq-abacavir sulfate ()
Abacavir sulfate ()
Abacavir (1592U89) ()
ABACAVIR SUCCINATE ()
Abacavir (sulfate) ()
Avacavir ()
NSC-742406 ()
Abacaviri sulfas ()
Abamune ()
Abacavir sulfate component of triumeq ()
Abacavir sulfate component of trizivir ()
Abacavir sulfate component of kivexa ()
Abacavir sulfate racemic ()
Abacavir (as sulfate) ()
1592U89 SULFATE ()
Abacavir sulfate component of epzicom ()
NSC-760063 ()
DRG-0257 ()
Abacavir sulphate ()
Abacavir-d4 ()
P&D ID
PD009146
CAS
188062-50-2
136470-78-5
216699-07-9
1260619-56-4
Tags
available
prodrug
drug
drug candidate
Approved by
FDA
EMA
First approval
1998
Drug indication
HIV infection
Human immunodeficiency virus infection
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Abacavir is a nucleoside analogue reverse transcriptase inhibitor (NRTI) class antiretroviral drug. (GtoPdb)
DESCRIPTION Abacavir is an orally active and competitive nucleoside reverse transcriptase inhibitor. Abacavir can inhibits the replication of HIV. Abacavir shows anticancer activity in prostate cancer cell lines. Abacavir can trespass the blood-brain-barrier and suppresses telomerase activity[1][2][3].
PRICE 32
PRICE 32
DESCRIPTION Abacavir sulfate is a Nucleoside analog reverse transcriptase inhibitor (NRTI); guanosine analog used to treat HIV and AIDS. (BOC Sciences Bioactive Compounds)
DESCRIPTION Abacavir (Ziagen) is a nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS. (TargetMol Bioactive Compound Library)
DESCRIPTION Abacavir is an antiviral analog of guanosine, inhibiting the reverse transcriptase of HIV type 1 with an IC50 value of 5.3 μM. (BOC Sciences Bioactive Compounds)
DESCRIPTION Abacavir is an antiviral nucleoside reverse transcriptase inhibitor used in combination with other antiretrovirals for the treatment of HIV. (Enamine Bioactive Compounds)
DESCRIPTION Abacavir sulfate (Ziagen) , a nucleoside analogue, effectively utilize its antiviral activity (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
5
Compound Sets
26
AdooQ Bioactive Compound Library
A11115
A11120
BOC Sciences Bioactive Compounds
abacavir-cas-136470-78-5-item-84-57926
abacavir-sulfate-cas-216699-07-9-292240
Cayman Chemical Bioactives
36925
14746
30076
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1380
CHEMBL4303288
ChEMBL Drugs
CHEMBL1380
CHEMBL4303288
CHEMBL2106686
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB01048
DrugBank Approved Drugs
DB01048
DrugCentral
34
DrugCentral Approved Drugs
34
DrugMAP
DMMN36E
DrugMAP Approved Drugs
DMMN36E
Enamine Bioactive Compounds
EBC-14802
Enamine BioReference Compounds
Guide to Pharmacology
11152
MedChem Express Bioactive Compound Library
HY-17423
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
WR2TIP26VS
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
abacavir
abacavir-sulfate
TargetMol Bioactive Compound Library
T1267
T6367
External IDs
87
Properties
(calculated by RDKit )
Molecular Weight
286.15
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
3
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
2
cLogP
1.09
TPSA
101.88
Fraction CSP3
0.5
Chiral centers
2.0
Largest ring
6.0
QED
0.73
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
viral reverse transcriptase inhibitor
HIV Protease inhibitor
nucleoside reverse transcriptase inhibitor
Target
Human immunodeficiency virus type 1 reverse transcriptase
Apoptosis
HIV
HIV-1 reverse-transcriptase
Reverse Transcriptase
Telomerase
Indication
human immunodeficiency virus (HIV-1)
Biosynthetic Origin
Nucleoside
Therapeutic Indication
Antiviral
Therapeutic Class
Anti-HIV Agents
Pathway
Microbiology/virology
Proteases/Proteasome
Anti-infection
Cell Cycle/DNA Damage
Solubility
In Vitro:<br/>DMSO: ≥ 3 mg/mL (10.48 mM)
In vitro:<br/>10 mM in DMSO
Source data